DFine Announces First Commercial Cases With STAR™ Tumor Ablation System in Europe

Published: Oct 09, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN JOSE, Calif.--(BUSINESS WIRE)--DFINE, Inc., a fast-growing market leader in the treatment of spinal diseases, today announced the completion of the first European commercial cases with the STAR™ Tumor Ablation System for the palliative treatment of painful metastatic spinal tumors since the device received CE Mark approval last month.

Help employers find you! Check out all the jobs and post your resume.

Back to news